지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 212 - 216 (5page)
이용수
초록· 키워드
오류제보하기
Purpose This study was designed to evaluate the efficacy of a combination treatment of S-1 plus either irinotecan or docetaxel for advanced/metastatic non-small cell lung cancer (NSCLC) patients who have already failed 3 or more lines of treatment.
Materials and Methods This was a prospective single center phase II study. The eligible patients received S-1 40 mg/m2twice a day orally on days 1 though 14 combined with irinotecan 150 mg/m2on D1 only or docetaxel 35 mg/m2 on D1 and D8. The treatment was repeated every 3 weeks until disease progression,unacceptable toxicity, or patient refusal. The choice between the two regimens was made at the discretion of the treating physician.
Results A total of 14 patients participated in the study. There were 3 patients with squamous cell carcinoma,9 with adenocarcinoma, and 2 with NSCLC, NOS. Eight of the patients were male. There were 8 patients with an Eastern Cooperative Oncology Group (ECOG) of 1, and 6 patients with an ECOG of 2. All the patients had already been treated with platinum-based chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor therapy. Out of the 14 patients, 10 received irinotecan and S-1 and the other 4 received docetaxel and S-1. Twelve patients had also received pemetrexed. Disappointingly, there were no response from 2 patients with a stable disease, and therefore, as per the protocol, we stopped the study early. With a median follow-up time of 49months, the median survival time was 5.6 months (95% confidence interval, 4.3 to 6.9 months).
Conclusion S-1 containing doublets did not show activity in this population as a salvage treatment and further investigation cannot be recommended.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
Adjei AA / 2010 / Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed- based therapy in non-small cell lung cancer:
Chen YM / 2011 / Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status / J Chin Med Assoc 74 : 209 ~ 214
Fox E / 2002 / Clinical trial design for target-based therapy / Oncologist 7 : 401 ~ 409
Govindan R / 2011 / Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer / J Thorac Oncol 6 : 790 ~ 795
Han JY / 2003 / A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer / Clin Cancer Res 9 (16) : 5909 ~ 5914
Chen YM / 2011 / Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status / J Chin Med Assoc 74 : 209 ~ 214
Fox E / 2002 / Clinical trial design for target-based therapy / Oncologist 7 : 401 ~ 409
Govindan R / 2011 / Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer / J Thorac Oncol 6 : 790 ~ 795
Han JY / 2003 / A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer / Clin Cancer Res 9 (16) : 5909 ~ 5914
이 논문의 저자 정보
최근 본 자료
댓글(0)
0